<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Pipeline on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/pipeline/</link><description>Recent content in Pipeline on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Fri, 19 Jun 2026 06:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/pipeline/index.xml" rel="self" type="application/rss+xml"/><item><title>What's Next in Psoriatic Arthritis Therapy? A Look at the Pipeline</title><link>https://rheumatologydigest.org/posts/psoriatic-arthritis-pipeline/</link><pubDate>Fri, 19 Jun 2026 06:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/psoriatic-arthritis-pipeline/</guid><description>A 2026 review of the psoriatic arthritis pipeline, organised around two vectors — greater precision (dual IL-17A/F blockade, engineered molecular formats, selective oral TYK2 inhibition, oral IL-23R antagonism) and moving earlier to intercept the psoriasis-to-PsA transition — alongside metabolic and dual-targeted strategies.</description></item></channel></rss>